[{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"2e1082a5-a1f6-4914-a8d9-c58f5de1c0cb","acronym":"SEMS","url":"https://clinicaltrials.gov/study/NCT02537548","created_at":"2021-01-18T12:16:28.563Z","updated_at":"2024-07-02T16:35:14.218Z","phase":"","brief_title":"Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma","source_id_and_acronym":"NCT02537548 - SEMS","lead_sponsor":"University of Southern California","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 08/28/2015","start_date":" 08/28/2015","primary_txt":" Primary completion: 08/28/2025","primary_completion_date":" 08/28/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2024-03-18"},{"id":"37490ed2-95b7-4f75-ad66-5a70c8b0ed1a","acronym":"EDEN","url":"https://clinicaltrials.gov/study/NCT05529251","created_at":"2022-09-07T16:55:48.800Z","updated_at":"2024-07-02T16:35:22.125Z","phase":"Phase 2","brief_title":"De-escalation Study for Stage IIa/IIb \u003c 3 cm Seminoma","source_id_and_acronym":"NCT05529251 - EDEN","lead_sponsor":"Centre Leon Berard","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/06/2022","start_date":" 09/06/2022","primary_txt":" Primary completion: 09/06/2025","primary_completion_date":" 09/06/2025","study_txt":" Completion: 09/06/2030","study_completion_date":" 09/06/2030","last_update_posted":"2024-01-25"},{"id":"fc3bebd3-4c0e-45cc-a032-11c1ad881bfb","acronym":"SWOG-S1823","url":"https://clinicaltrials.gov/study/NCT04435756","created_at":"2021-01-18T21:21:24.405Z","updated_at":"2024-07-02T16:35:26.523Z","phase":"","brief_title":"A Study of miRNA 371 in Patients With Germ Cell Tumors","source_id_and_acronym":"NCT04435756 - SWOG-S1823","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 956","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-12-12"},{"id":"a20ca03c-e4c8-424b-9577-602d1900d998","acronym":"SWENOTECA-ABC","url":"https://clinicaltrials.gov/study/NCT02341989","created_at":"2021-01-18T11:07:54.417Z","updated_at":"2024-07-02T16:35:43.889Z","phase":"Phase 3","brief_title":"Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer","source_id_and_acronym":"NCT02341989 - SWENOTECA-ABC","lead_sponsor":"St. Olavs Hospital","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • etoposide IV • bleomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 12/01/2035","primary_completion_date":" 12/01/2035","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2023-07-06"},{"id":"4ccc2c43-cf80-4471-8f20-ea4d38f5f9ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01037790","created_at":"2021-01-18T04:04:21.968Z","updated_at":"2024-07-02T16:36:33.413Z","phase":"Phase 2","brief_title":"Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer","source_id_and_acronym":"NCT01037790","lead_sponsor":"Abramson Cancer Center of the University of Pennsylvania","biomarkers":" HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2","pipe":" | ","alterations":" KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation","tags":["HER-2 • KRAS • BRAF • ER • RB1 • CCND1 • CDK4 • CCND2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • BRAF mutation • CCND1 amplification • CDK4 amplification • RB1 positive • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2021-03-11"},{"id":"819294ba-74b9-4f50-84d9-79e3893ca5a2","acronym":"Car-PET","url":"https://clinicaltrials.gov/study/NCT02272816","created_at":"2021-01-18T10:41:28.011Z","updated_at":"2024-07-02T16:37:03.475Z","phase":"Phase 2","brief_title":"Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma","source_id_and_acronym":"NCT02272816 - Car-PET","lead_sponsor":"Barts \u0026 The London NHS Trust","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 02/13/2012","start_date":" 02/13/2012","primary_txt":" Primary completion: 10/13/2017","primary_completion_date":" 10/13/2017","study_txt":" Completion: 10/13/2017","study_completion_date":" 10/13/2017","last_update_posted":"2019-01-25"},{"id":"04610283-47d7-4091-9c18-1ccd26727c12","acronym":"","url":"https://clinicaltrials.gov/study/NCT00957905","created_at":"2021-01-18T03:43:42.428Z","updated_at":"2024-07-02T16:37:24.527Z","phase":"Phase 2","brief_title":"Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors","source_id_and_acronym":"NCT00957905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • oxaliplatin • leucovorin calcium • alvocidib (DSP-2033) • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-03-10"},{"id":"be9ba197-ee9d-4624-812d-e22a854862ba","acronym":"SEMITEP","url":"https://clinicaltrials.gov/study/NCT01887340","created_at":"2021-01-18T08:28:22.200Z","updated_at":"2024-07-02T16:37:31.427Z","phase":"Phase 2","brief_title":"Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma","source_id_and_acronym":"NCT01887340 - SEMITEP","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2016-06-09"}]